Adam D. Gridley

Adam Gridley has served as chief executive officer at Allay Therapeutics since November 2020. He has over 25 years of experience in the biotechnology, medical device, and pharmaceutical industries leading venture capital-backed startups to mature, fully integrated commercial organizations.

Prior to Allay, Adam was the CEO of Entera Bio (NASDAQ: ENTX), a biotechnology company specializing in the oral delivery of large molecules and biologics, as well as the president and CEO of Histogenics (NASDAQ: HSGX), a cell therapy and biologics company developing novel therapeutics for cartilage defects, where he led a completed IPO, multiple fundraisings and strategic transactions. Prior to Histogenics, Adam was senior vice president, technical operations, and global site head at Merz Pharma. He was also previously senior vice president of corporate development at BioForm Medical (NASDAQ: BFRM) prior to the company’s sale to Merz, where he played a key role in an IPO as well as acquisitions and product launches. Adam was previously on the board of directors of the Alliance for Regenerative Medicine and is on the board of advisors for Life Science Cares. He also serves as the executive chairman of LifeSprout, a Johns Hopkins founded company developing aesthetic and regenerative medicine products. Adam holds a bachelor’s degree and MBA from the University of Denver.